Advances of molecular imaging probes for the diagnosis of Alzheimer's disease

Current Alzheimer Research

Volumn 11, Issue 3, 2014, Pages 221-231

  Zhou, Ming ^a   Wang, Xiaobo ^a   Liu, Zhiguo ^a   Yu, Lun ^a   Hu, Shuo ^a,b   Chen, Lizhang ^a   Zeng, Wenbin ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Biomarker; Molecular imaging; PET; Probe

Indexed keywords

CONGO RED; FLORBETAPIR F 18; FLUORESCENT DYE; FLUORODEOXYGLUCOSE F 18; PITTSBURGH COMPOUND B; TECHNETIUM 99M; THIOFLAVINE;

ALZHEIMER DISEASE; ARTICLE; CLINICAL PRACTICE; DISEASE CLASSIFICATION; FOOD AND DRUG ADMINISTRATION; HUMAN; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOIODINATION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ALZHEIMER DISEASE; DIAGNOSTIC TECHNIQUES, RADIOISOTOPE; HUMANS; MOLECULAR IMAGING; MOLECULAR PROBES;

EID: 84897452095     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205011666140131121259     Document Type: Article

References (78)

1. Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde [About a peculiar disease of the cere all gemeine bral cortex]. Zeitschrift furPsychiatrie und Psychisch-Gerichtlich Medizin 64: 146-148 (1907).
2. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 366(9503): 2112-7 (2005).
3. Alzheimer's Disease International World Alzheimer Report. London, United Kingdom: King's College (2009).
4. Brooks LG, Loewenstein DA. Assessing the progression of mild cognitive impairment to Alzheimer's disease: current trends and future directions. Alzheimers Res Ther 2(5): 28 (2010).
5. Dimou E, Booij J, Rodrigues M, Prosch H. Attems J, Knoll P, et al. Amyloid PET and MRI in Alzheimer's disease and mild cognitive impairment. Curr Alzheimer Res 6(3): 312-9 (2009).
6. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 17(5): 545-80 (2003).
7. Herholz K. Molecular imaging in Alzheimer's disease. Euro Neuro Rev 6(1): 16-20 (2011).
8. Kallmerten AE, Jones GB. Microwave accelerated synthesis of PET image contrast agents for AD research. Curr Alzheimer Res 7(3): 251-4 (2010).
9. Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-aryl benzothiazoles as amyloid imaging agents. J Med Chem 46(13): 2740-54 (2003).
10. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, Ringheim A, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 29(10): 1456-65 (2008).
11. Juréus A, Swahn BM, Sandell J, Jeppsson F, Johnson AE, Johnström P, et al. Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand. J Neurochem 114(3): 784-94 (2010).
12. Steven K, Emma MT, Stephen MH, Cristian AS, Steen J, Robin JT, et al. Imaging imidazoline-I2 binding sites in porcine brain using11C-BU99008. J Nucl Med 54(1): 139-44 (2013).
13. Verhoeff NP, Wilson AA, Takeshita S, Trop L, Hussey D, Singh K, et al. In vivo imaging of Alzheimer disease β-amyloid with [11C]SB-13 PET. Am J Geriatr Psych 12(6), 584-95 (2004).
14. Chen Q, Prior M, Dargusch R, Roberts A, Riek R, Eichmann C, et al. A novel neurotrophic drug for cognitive enhancement and Alzheimer's disease. PLoS One 6(12): e27865 (2011).
15. Marcone A, Garibotto V, Moresco RM, Florea I, Panzacchi A, Carpinelli A, et al. [11C]-MP4A PET cholinergic measurements in amnestic mild cognitive impairment, probable Alzheimer's disease, and dementia with lewy bodies: a bayesian method and voxelbased analysis. J Alzheimers Dis 31(2): 387-99 (2012).
16. Kudo Y, Okamura N, Furumoto S, Tashiro M, Furukawa K, Maruyama M, et al. 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6-(2[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J Nucl Med 48(4): 553-61 (2007).
17. Nyberg S, Jönhagen ME, Cselényi Z, Halldin C, Julin P, Olsson H, et al. Detection of amyloid in Alzheimer's disease with positron emission tomography using[11C]AZD2184. Eur J Nucl Med Mol Imaging 36(11): 1859-63 (2009).
18. Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, et al. Localization of neurofibrillary tangles and betaamyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psych 10(1): 24-35 (2002).
19. Teng E, Kepe V, Frautschy SA, Liu J, Satyamurthy N, Yang F, et al. [F-18]FDDNP micro PET imaging correlates with brain Aβ burden in a transgenic rat model of Alzheimer disease: effects of aging, in vivo blockade, and anti-Aβ antibody treatment. Neurobiol Dis 43(3): 565-75 (2011).
20. Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, et al. Imaging of amyloid in Alzheimer's disease with 18FBAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 7(2): 129-35 (2008).
21. Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18 F-AV-45 (florbetapir F 18). J Nucl Med 51(6): 913-20 (2010).
22. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 305(3): 275-83 (2011).
23. Damian BC, Heribert SW, Tobias H, Andrea V, Balázs G, Miklos T, et al. Preclinical characterization of a novel class of 18F-labeled PET tracers amyloid-β. J Nucl Med 53: 1794-801 (2012).
24. Blennow K, Zetterberg H. Pinpointing plaques with PIB. Nat Med 12(7): 753-4 (2006).
25. Nordberg A. PET imaging of amyloid in Alzheimer's disease. Lancet Neurol 3(9): 519-27 (2004).
26. Groom GN, Junck L, Foster NL, Frey KA, Kuhl DE. PET of peripheral benzodiazepine binding sites in the microgliosis of Alzheimer's disease. J Nucl Med 36(12): 2207-10 (1995).
27. Valotassiou V, Archimandritis S, Sifakis N, Papatriantafyllou J, Georgoulias P. Alzheimer's disease: SPECT and PET tracers for beta-amyloid imaging. Curr Alzheimer Res 7(6): 477-86 (2010).
28. Zhuang ZP, Kung MP, Hou C, Skovronsky DM, Gur TL, Plössl K, et al. Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates. J Med Chem 44(12): 1905-14 (2001).
29. Kung HF, Lee CW, Zhuang ZP, Kung MP, Hou C, Plossl K. Novel stilbenes as probes for amyloid plaques. J Am Chem Soc 123(50): 12740-1 (2001).
30. Ono M, Haratake M, Nakayama M, Kaneko Y, Kawabata K, Mori H, et al. Synthesis and biological evaluation of (E)-3-styrylpyridine derivatives as amyloid imaging agents for Alzheimer's disease. Nucl Med Biol 32(4): 329-35 (2005).
31. Qu W, Kung MP, Hou C, Benedum TE, Kung HF. Novel styrylpyridines as probes for SPECT imaging of amyloid plaques. J Med Chem 50(9): 2157-65 (2007).
32. Qu W, Kung MP, Hou C, Jin LW, Kung HF. Radioiodinated azadiphenylacetylenes as potential SPECT imaging agents for β-amyloid plaque detection. Bioorg Med Chem Lett 17(13): 3581-4 (2007).
33. Newberg AB, Wintering NA, Plossl K, Hochold J, Stabin MG, Watson M, et al. Safety, biodistribution, and dosimetry of 123 IIMPY: a novel amyloid plague-imaging agent for the diagnosis of Alzheimer's disease. J Nucl Med 47(5): 748-54 (2006).
34. Zhuang ZP, Kung MP, Hou C, Skovronsky DM, Gur TL, Plössl K, et al. Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates. J Med Chem 44(12): 1905-14 (2001).
35. Zhuang ZP, Kung MP, Hou C, Plossl K, Skovronsky D, Gur TL, et al. IBOX (2-(4'-dimethylaminophenyl)-6-iodobenzoxazole): a ligand for imaging amyloid plaques in the brain. Nucl Med Biol 28(8): 887-94 (2001).
36. Ono M, Kung MP, Hou C, Kung HF. Benzofuran derivatives as Aβ-aggregate-specific imaging agents for Alzheimer's disease. Nucl Med Biol 29(6): 633-42 (2002).
37. Chandra R, Kung MP, Kung HF. Design, synthesis, and structureactivity relationship of novel thiophene derivatives for betaamyloid plaque imaging. Bioorg Med Chem Lett 16(5): 1350-2 (2006).
38. Cui M, Ono M, Kimura H, Kawashima H, Liu BL, Saji H. Radioiodinated benzimidazole derivatives as single photon emission computed tomography probes for imaging of β-amyloid plaques in Alzheimer's disease. Nucl Med Biol 38(3): 313-20 (2011).
39. Kung MP, Hou C, Zhuang ZP, Zhang B, Skovronskyb D, Trojanowskib JQ, et al. IMPY: animproved thioflavin-T derivative for in vivo labeling of β-amyloid plaques. Brain Res 956(2): 202-10 (2002).
40. Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M. Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. J Neurochem 87(1): 172-81 (2003).
41. Ono M, Yoshida N, Ishibashi K, Haratake M, Arano Y, Mori H, et al. Radioiodinated flavones for in vivo imaging of β-amyloid plaques in the brain. Med Chem 48(23): 7253-60 (2005).
42. Ono M, Hori M, Haratake M, Tomiyama T, Mori H, Nakayama M. Structure-activity relationship of chalcones and related derivatives as ligands for detecting of β-amyloid plaques in the brain. Bioorg Med Chem 15(19): 6388-96 (2007).
43. Ono M, Haratake M, Mori H, Nakayama M. Novel chalcones as probes for in vivo imaging of β-amyloid plaques in Alzheimer's brains. Bioorg Med Chem 15(21): 6802-9 (2007).
44. Ono M, Maya Y, Haratake M, Ito K, Mori H, Nakayama M. Aurones serve as probes of β-amyloid plaques in Alzheimer's disease. Biochem Biophys Res Commun 361(1): 116-21 (2007).
45. Maya Y, Ono M, Watanabe H, Haratake M, Saji H, Nakayama M. Novel radioiodinated aurones as probes for SPECT imaging of β-amyloid plaques in the brain. Bioconjug Chem 20(1): 95-101 (2009).
46. Cui M, Ono M, Kimura H, Liu BL, Saji H. Synthesis and biological evaluation of indole-chalcone derivatives as β-amyloid imaging probe. Bioorg Med Chem Lett 21(3): 980-2 (2011).
47. Hom RK, Katzenellenbogen JA. Technetium-99m-labeled receptor-specific small-molecule radiopharmaceuticals: recent developments and encouraging results. Nucl Med Biol 24(6): 485-98 (1997).
48. Zhen W, Han H, Anguiano M, Lemere CA, Cho CG, Lansbury PT. Synthesis and amyloid binding properties of rhenium complexes: preliminary progress toward a reagent for SPECT imaging of Alzheimer's disease brain. J Med Chem 42(15): 2805-15 (1999).
49. Serdons K, Verduyckt T, Cleynhens J, Terwinghe C, Mortelmans L, Bormans G, et al. Synthesis and evaluation of a (99m)Tc-BATphenyl-benzothiazole conjugate as a potential in vivo tracer for visualization of amyloid beta. Bioorg Med Chem Lett 17(22): 6086-90 (2007).
50. Chen X, Yu P, Zhang L, Liu B. Synthesis and biological evaluation of 99mTc, Re-monoamine-monoamide conjugated to 2-(4-aminophenyl) benzothiazole as potential probes for β-amyloid plaques in the brain. Bioorg Med Chem Lett 18(4): 1442-5 (2008).
51. Ono M, Ikeoka R, Watanabe H, Kimura H, Fuchigami T, Haratake M, et al. Synthesis and evaluation of novel chalcone derivatives with 99mTc/Re complexes as potential probes for detection of β-amyloid plaques. ACS Chem Neurosci 1(9): 598-607 (2010).
52. Ono M, Ikeoka R, Watanabe H, Kimura H, Fuchigami T, Haratake M, et al. 99mTc/Re complexes based on flavonel and aurone as SPECT probes for imaging cerebral β-amyloid plaques. Bioorg Med Chem Lett 20 (19): 5743-8 (2010).
53. Cui M, Tang R, Li Z, Ren H, Liu B. 99mTc-and Re-labeled 6-dialkylamino-2-naphthylethylidene derivatives as imaging probes for β-amyloid plaques. Bioorg Med Chem Lett 21(3): 1064-8 (2011).
54. Li ZJ, Cui MC, Dai JP, Wang XD, Yu PR, Yang YP, et al. Novel cyclopentadienyl tricarbonyl complexes of 99mTc mimicking chalcone as potential single-photon emission computed tomography imaging probes for β-Amyloid plaques in brain. J Med Chem 56: 471-82 (2013).
55. Higuchi M, Iwata N, Matsuba Y, Sato K, Sasamoto K, Saido TC. 19F and 1H MRI detection of β-amyloid plaques in vivo. Nat Neurosci 8(4): 527-33 (2005).
56. Wengenack TM, Curran GL, Poduslo, JF. Targeting Alzheimer amyloid plaques in vivo. Nat Biotechnol 18(8): 868-72 (2000).
57. Poduslo JF, Wengenack TM, Curran GL, Wisniewski T, Sigurdsson EM, Macura SI, et al. Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol Dis 11(2): 315-29 (2002).
58. Poduslo JF, Curran GL, Peterson JA, McCormick DJ, Fauq AH, Khan MA, et al. Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood-brain barrier permeability, and in vivo targeting to Alzheimer's disease amyloid plaques. Biochemistry 43(20): 6064-75 (2004).
59. Schmidt ML, Schuck T, Sheridan S, Kung MP, Kung H, Zhuang ZP, et al. The fluorescent Congo red derivative, (trans, trans)-1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene (BSB), labels diverse beta-pleated sheet structures in postmortem human neurodegenerative disease brains. Am J Pathol 159(3): 937-43 (2001).
60. Mathis CA, Bacskai BJ, Kajdasz ST, McLellan ME, Frosch MP, Hyman BT, et al. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett 12(3): 295-8 (2002).
61. Hong MC, Im YK, Choi JY, Yang SQ, Rhee H, Ryu YH, et al. Synthesis and evaluation of stilbene derivatives as a potential imaging agent of amyloid plaques. Bioorg Med Chem 18(22): 7724-30 (2010).
62. Voropai ES, Samtsov MP, Kaplevskii KN, Maskevich AA, Stepuro VI, Povarova OI, et al. Spectral properties of thioflavin T and its complexes with amyloid fibrils. J Appl Spectrosc 70(6): 868-74 (2003).
63. Khurana R, Uversky VN, Nielsen L, Fink AL. Is Congo red an amyloid-specific dye? J Biol Chem 276(25): 22715-21 (2001).
64. Nesterov EE, Skoch J, Hyman BT, Klunk WE, Bacskai BJ, Swager TM. In vivo optical imaging of amyloid aggregates in brain: design of fluorescent markers. Angew Chem Int Ed Engl 44(34): 5452-56 (2005).
65. Raymond SB, Skoch J, Hills ID, Nesterov EE, Swager TM, Bacskai BJ. Smart optical probes for near-infrared fluorescence imaging of Alzheimer's disease pathology. Eur J Nucl Med Mol Imaging 35(5): 93-98 (2008).
66. Hintersteiner M, Enz A, Frey P, Jaton AL, Kinzy W, Kneuer R, et al. In vivo detection of amyloid-beta deposits by near-infrared imaging using an oxazine-derivative probe. Nat Biotechnol 23(5): 577-83 (2005).
67. Ran C, Xu X, Raymond SB, Ferrara BJ, Neal K, Bacskai BJ, et al. Design, synthesis, and testing of difluoroboron derivatized curcumins as near-infrared probes for in vivo detection of amyloid deposits. J Am Chem Soc 131(42): 15257-61 (2009).
68. Okamura N, Mori M, Furumoto S, Yoshikawa T, Harada R, Ito S, et al. In vivo detection of amyloid plaques in the mouse brain using the near-infrared fluorescence probe THK-265. J Alzheimers Dis 23(1): 37-48 (2011).
69. Chang WM, Dakanali M, Capule CC, Sigurdson CJ, Yang J, Theodorakis EA. ANCA: a family of fluorescent probes that bind and stain amyloid plaques in human tissue. ACS Chem Neurosci 2(5): 249-55 (2011).
70. Liu K, Guo TL, Chojnacki J, Lee HG, Wang X, Siedlak SL, et al. Bivalent ligand containing curcumin and cholesterol as fluorescence probe for Aβ plaques in Alzheimer's disease. Chem Neurosci 3(2): 141-46 (2012).
71. Robert Ta, Mojmir S, Joshua HK, Alex XL, Francisco S, Martinez S, et al. A dual magnetic resonance imaging/fluorescent contrast agent for Cathepsin-D detection. Contrast Media Mol Imaging 8(2): 127-39 (2013).
72. Duff K, Kuret J, Congdon EE. Disaggregation of Tau as a therapeutic approach to Tauopathies. Curr Alzheimer Res 7(3): 235-40 (2010).
73. Ojida A, Sakamoto T, Inoue MA, Fujishima SH, Lippens G, Hamachi I. Fluorescent BODIPY-based Zn(II) complex as a molecular probe for selective detection of neurofibrillary tangles in the brains of Alzheimer's disease patients. J Am Chem Soc 131(18): 6543-48 (2009).
74. Takahashi T, Ohta K, Mihara H. Rational design of amyloid beta peptide-binding proteins: pseudo-abeta beta-sheet surface presented in green fluorescent protein binds tightly and preferentially to structured Abeta. Proteins 78(2): 336-47 (2010).
75. Takahashi T, Mihara H. FRET detection of amyloid β-peptide oligomerization using a fluorescent protein probe presenting a pseudo-amyloid structure. Chem Commun 48(10): 1568-70 (2012).
76. Hong MC, Kim YK, Choi JY, Yang SQ, Rhee H, Ryu YH, et al. Synthesis and evaluation of stilbene derivatives as a potential imaging agent of amyloid plaques. Bioorg Med Chem 18(22): 7724-30 (2010).
77. Han BH, Zhou ML, Vellimana AK, Milner E, Kim DH, Greenberg JK, et al. Resorufin analogs preferentially bind cerebrovascular amyloid: potential use as imaging ligands for cerebral amyloid angiopathy. Mol Neurodegener 6: 86 (2011).
78. Nordberg A, Rinne JO, Kadir A, Langstrom B. The use of PET in Alzheimer disease. Nat Rev Neurol 6: 78-87 (2010).